MBX 2044

Drug Profile

MBX 2044

Alternative Names: MBX 102 Second Generation; MBX 102 SG; MBX-2044

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Metabolex
  • Class Antihyperglycaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 11 Nov 2009 MBX 2044 is still in active development
  • 28 Mar 2008 Metabolex completes the phase IIa trial in Type 2 diabetes in USA
  • 20 Dec 2006 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top